Premium
Effectiveness of alendronate treatment in postmenopausal women with osteoporosis: relationship with BsmI vitamin D receptor genotypes
Author(s) -
Palomba Stefano,
Numis Fabio Giuliano,
Mossetti Giuseppe,
Rendina Domenico,
Vuotto Pietro,
Russo Tiziana,
Zullo Fulvio,
Nappi Carmine,
Nunziata Vincenzo
Publication year - 2003
Publication title -
clinical endocrinology
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 1.055
H-Index - 147
eISSN - 1365-2265
pISSN - 0300-0664
DOI - 10.1046/j.1365-2265.2003.01724.x
Subject(s) - calcitriol receptor , medicine , endocrinology , osteoporosis , deoxypyridinoline , bone mineral , urinary system , osteocalcin , vitamin d and neurology , creatinine , bone remodeling , chemistry , alkaline phosphatase , biochemistry , enzyme
Summary objective To assess whether there is a relationship between the effectiveness of alendronate treatment in postmenopausal women with osteoporosis and BsmI vitamin D receptor (VDR) genotypes. design Prospective baseline‐controlled clinical trial. patients Sixty‐eight Italian osteoporotic women were enrolled and treated with alendronate at a dose of 10 mg/day for 12 months. measurements At entry and after treatment, lumbar bone mineral density (BMD) and serum osteocalcin (OC) and urinary deoxypyridinoline/creatinine ratio (DPD‐Cr) levels were evaluated. DNA was extracted from blood and analysed for the BsmI polymorphism of the VDR gene. results The mean percentage (% ± SD) change from baseline in lumbar BMD was significantly higher ( P < 0·01) in bb than in BB BsmI VDR genotypes (7·92 ± 4·31 vs. 3·40 ± 1·81). No significant difference in lumbar BMD was observed in Bb VDR patients (6·01 ± 3·89) in comparison with other groups. The mean percentage of change in serum OC and urinary DPD‐Cr levels was significantly ( P < 0·01) lower in individuals with bb than in those with BB BsmI VDR genotypes (−14·34 ± 2·87 vs. −10·39 ± 1·43 and −9·61 ± 5·56 vs. −4·61 ± 2·31). No significant difference in serum OC and urinary DPD‐Cr levels was observed in Bb VDR patients (−12·31 ± 2·11 and −6·52 ± 2·65) in comparison with other groups. conclusion The different BsmI vitamin D receptor genotypes modify the pharmacological response to alendronate treatment in postmenopausal women with osteoporosis.